JP2011522827A5 - - Google Patents

Download PDF

Info

Publication number
JP2011522827A5
JP2011522827A5 JP2011512645A JP2011512645A JP2011522827A5 JP 2011522827 A5 JP2011522827 A5 JP 2011522827A5 JP 2011512645 A JP2011512645 A JP 2011512645A JP 2011512645 A JP2011512645 A JP 2011512645A JP 2011522827 A5 JP2011522827 A5 JP 2011522827A5
Authority
JP
Japan
Prior art keywords
medicament
mammals
mammals use
purity
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011512645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522827A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/046256 external-priority patent/WO2009149258A2/en
Publication of JP2011522827A publication Critical patent/JP2011522827A/ja
Publication of JP2011522827A5 publication Critical patent/JP2011522827A5/ja
Pending legal-status Critical Current

Links

JP2011512645A 2008-06-04 2009-06-04 ６−［（４ｓ）−２−メチル−４−（２−ナフチル）−１，２，３，４−テトラヒドロイソキノリン−７−イル］ピリダジン−３−アミンの結晶形 Pending JP2011522827A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5871708P 2008-06-04 2008-06-04
US61/058,717 2008-06-04
PCT/US2009/046256 WO2009149258A2 (en) 2008-06-04 2009-06-04 Crystalline form of 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine

Publications (2)

Publication Number Publication Date
JP2011522827A JP2011522827A (ja) 2011-08-04
JP2011522827A5 true JP2011522827A5 (enExample) 2012-08-09

Family

ID=41277466

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011512645A Pending JP2011522827A (ja) 2008-06-04 2009-06-04 ６−［（４ｓ）−２−メチル−４−（２−ナフチル）−１，２，３，４−テトラヒドロイソキノリン−７−イル］ピリダジン−３−アミンの結晶形
JP2011512646A Expired - Fee Related JP5567557B2 (ja) 2008-06-04 2009-06-04 テトラヒドロイソキノリンの製造方法
JP2014100580A Pending JP2014169312A (ja) 2008-06-04 2014-05-14 テトラヒドロイソキノリンの製造方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011512646A Expired - Fee Related JP5567557B2 (ja) 2008-06-04 2009-06-04 テトラヒドロイソキノリンの製造方法
JP2014100580A Pending JP2014169312A (ja) 2008-06-04 2014-05-14 テトラヒドロイソキノリンの製造方法

Country Status (9)

Country Link
US (4) US8445494B2 (enExample)
EP (2) EP2280956A2 (enExample)
JP (3) JP2011522827A (enExample)
KR (1) KR20110011653A (enExample)
CN (2) CN102112465B (enExample)
AR (1) AR071997A1 (enExample)
ES (1) ES2652462T3 (enExample)
TW (1) TW201002682A (enExample)
WO (2) WO2009149259A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063766A1 (en) 2004-07-15 2006-03-23 Molino Bruce F Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin
DE602006015523D1 (de) * 2005-12-06 2010-08-26 Neurosearch As Neue diazabicyclische arylderivate und medizinische verwendung dafür
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) * 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
PE20120373A1 (es) * 2009-05-12 2012-05-17 Albany Molecular Res Inc 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina
JP2012526823A (ja) 2009-05-12 2012-11-01 アルバニー モレキュラー リサーチ， インコーポレイテッド アリール、ヘテロアリール、および複素環置換テトラヒドロイソキノリンならびにそれらの使用
US9045468B2 (en) 2010-08-17 2015-06-02 Albany Molecular Research, Inc. 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
NO2686520T3 (enExample) 2011-06-06 2018-03-17
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014159501A2 (en) * 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Processes for preparing tetrahydroisoquinolines
CN103601699A (zh) * 2013-11-04 2014-02-26 南京大学 一类1,3,4-噻二唑-2-酰胺衍生物及其制备方法
TW201946625A (zh) 2013-11-15 2019-12-16 美商阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途
AU2019265629B2 (en) 2018-05-09 2024-09-12 Akebia Therapeutics, Inc. Process for preparing 2-((5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino)acetic acid
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947456A (en) * 1970-01-06 1976-03-30 Hoffman-La Roche Inc. Substituted 4-phenyl isoquinolines
US3666763A (en) * 1970-01-06 1972-05-30 Hoffmann La Roche 4-phenyl isoquinolines and process for preparing same
CH527194A (de) 1970-01-06 1972-08-31 Hoffmann La Roche Verfahren zur Herstellung von Isochinolin-Derivaten
GB1504424A (en) * 1975-08-09 1978-03-22 Beecham Group Ltd Isoquinoline-derived aminoethers
US4340600A (en) * 1980-05-22 1982-07-20 Smithkline Corporation Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines
DE3333994A1 (de) * 1983-09-21 1985-04-04 Troponwerke GmbH & Co KG, 5000 Köln Neue pyridoindolderivate, verfahren zu ihrer herstellung und ihre verwendung
US4843071A (en) * 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
WO1990005525A1 (en) 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
BG49761A1 (en) 1989-04-24 1992-02-14 Vissh Khim T I 4- (4'- chalophenyl)- 2- methyl- 1, 2, 3, 4- tetrahydroisohinolines and method for its preparation
US5164372A (en) 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
IE903957A1 (en) 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
FR2654725B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2654726B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone et leur preparation.
GB8929070D0 (en) 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
WO1991009844A1 (en) 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
EP0515681A4 (en) 1990-02-15 1993-12-29 Fujisawa Pharmaceutical Co., Ltd. Peptide compound
EP0532527B1 (en) 1990-06-01 1994-11-09 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
DK0540526T3 (da) 1990-07-23 1995-04-18 Pfizer Quinuclidinderivater
AU651145B2 (en) 1990-09-28 1994-07-14 Pfizer Inc. Fused ring analogs of nitrogen containing nonaromatic heterocycles
GB9023116D0 (en) 1990-10-24 1990-12-05 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
JPH04193867A (ja) 1990-11-23 1992-07-13 Nippon Shinyaku Co Ltd イソキノリノール誘導体及び医薬
DE69114117T2 (de) 1990-12-21 1996-03-21 Fujisawa Pharmaceutical Co Neue Verwendung von Peptidderivat.
EP0566589A1 (en) 1991-01-10 1993-10-27 Pfizer Inc. N-alkyl quinuclidinium salts as substance p antagonists
ATE154354T1 (de) 1991-02-11 1997-06-15 Merck Sharp & Dohme Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung
EP0573522B1 (en) 1991-03-01 1994-12-14 Pfizer Inc. 1-azabicyclo[3.2.2]nonan-3-amine derivatives
PL169993B1 (pl) 1991-03-26 1996-09-30 Pfizer Sposób wytwarzania podstawionych piperydyn PL PL PL PL
FR2677361A1 (fr) 1991-06-04 1992-12-11 Adir Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2676053B1 (fr) 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676055B1 (fr) 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676442B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2676443B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole et leur preparation.
FR2676446B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives du thiopyranopyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2676447B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives du thiopyranopyrrole et leur preparation.
US5288730A (en) 1991-06-24 1994-02-22 Merck Sharp & Dohme Limited Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
EP0536817A1 (en) 1991-07-05 1993-04-14 MERCK SHARP & DOHME LTD. Azabicyclic compounds as tachykinin antagonists
JPH06509332A (ja) 1991-07-05 1994-10-20 メルク　シヤープ　エンド　ドーム　リミテツド 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
CA2112397A1 (en) 1991-08-20 1993-03-04 Raymond Baker Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
ATE195867T1 (de) 1991-09-20 2000-09-15 Glaxo Group Ltd Neue medizinische indikation für tachykinin- antagonisten
CA2083891A1 (en) 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
GB2266529A (en) 1992-05-01 1993-11-03 Merck Sharp & Dohme Tetrahydroisoquinoline derivatives
IL106142A (en) 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
GB2268931A (en) 1992-07-22 1994-01-26 Merck Sharp & Dohme Azabicyclic tachykinin-receptor antagonists
GB2269170A (en) 1992-07-29 1994-02-02 Merck Sharp & Dohme Azatricyclic tachykinin antagonists
GB9216911D0 (en) 1992-08-10 1992-09-23 Merck Sharp & Dohme Therapeutic agents
NO179904C (no) 1992-09-04 1997-01-08 Takeda Chemical Industries Ltd Kondenserte heterocykliske forbindelser og deres anvendelse
GB2271566A (en) 1992-10-14 1994-04-20 Merck & Co Inc HIV integrase inhibitors
GB9222486D0 (en) 1992-10-26 1992-12-09 Merck Sharp & Dohme Therapeutic agents
JPH06153997A (ja) 1992-11-27 1994-06-03 Canon Inc 検出信号増幅による標的核酸の検出方法
DK154192D0 (da) * 1992-12-23 1992-12-23 Neurosearch As Heterocycliske forbindelser
EP0610793A1 (en) 1993-02-08 1994-08-17 Takeda Chemical Industries, Ltd. Tetracyclic morpholine derivatives and their use or analgesics
EP0634402A1 (en) 1993-07-14 1995-01-18 Takeda Chemical Industries, Ltd. Isochinolinone derivatives, their production and use
US5607939A (en) * 1994-04-28 1997-03-04 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
IL113472A0 (en) 1994-04-29 1995-07-31 Lilly Co Eli Non-peptidyl tachykinin receptor antogonists
EP0686629A3 (en) 1994-06-10 1999-02-10 Eli Lilly And Company Cyclohexyl tachykinine receptor antagonists
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
HUT77948A (hu) 1994-07-12 1998-12-28 Eli Lilly And Co., Heterociklusos tachikinin-receptor antagonisták
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
CA2154116A1 (en) 1994-07-22 1996-01-23 Philip Arthur Hipskind 1-aryl-2-acetamidopentanone derivatives for use as tachykinin receptor antagonists
GB9415997D0 (en) 1994-08-08 1994-09-28 Merck Sharp & Dohme Therapeutic agents
ES2107118T3 (es) 1994-08-29 1997-11-16 Akzo Nobel Nv Procedimiento para la preparacion de diesteres cuaternarios.
GB9418545D0 (en) 1994-09-15 1994-11-02 Merck Sharp & Dohme Therapeutic agents
US5457107A (en) 1994-09-16 1995-10-10 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
TW397825B (en) 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
FR2725986B1 (fr) 1994-10-21 1996-11-29 Adir Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE69534213T2 (de) 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
GB9421709D0 (en) 1994-10-27 1994-12-14 Zeneca Ltd Therapeutic compounds
EP0714891A1 (en) 1994-11-22 1996-06-05 Eli Lilly And Company Heterocyclic tachykinin receptor antagonists
FR2729951B1 (fr) 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
NO309272B1 (no) 1995-03-24 2001-01-08 Takeda Chemical Industries Ltd Cykliske forbindelser, preparater inneholdende forbindelsene samt mellomprodukter for fremstilling av forbindelsene
GB9513118D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
RU2135494C1 (ru) 1995-12-01 1999-08-27 Санкио Компани Лимитед Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина
US6121261A (en) * 1997-11-19 2000-09-19 Merck & Co., Inc. Method for treating attention deficit disorder
DK1140761T3 (da) * 1999-01-12 2004-01-26 Clariant Finance Bvi Ltd Benzophenoner og anvendelse deraf som fotoinitiatorer
US7163949B1 (en) * 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
MXPA02004330A (es) * 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
MXPA02006660A (es) * 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
US6664256B1 (en) * 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
JP5132864B2 (ja) * 2000-07-11 2013-01-30 アルバニー モレキュラー リサーチ， インコーポレイテッド ４−フェニル置換テトラヒドロイソキノリンおよびその使用方法
US6911453B2 (en) * 2001-12-05 2005-06-28 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
EP1852415B1 (en) * 2002-07-09 2009-10-07 Lonza Ag Process for the preparation of N-monosubstituted beta-amino alcohols
US20060063766A1 (en) * 2004-07-15 2006-03-23 Molino Bruce F Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin
US20060111385A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
US20060111393A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US20060111394A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US7956050B2 (en) * 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
JP4193867B2 (ja) 2006-05-02 2008-12-10 ソニー株式会社 ＧａＮ系半導体レーザの製造方法
WO2008005368A2 (en) * 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
BRPI0714199A2 (pt) * 2006-07-04 2012-12-25 Janssen Pharmaceutica Nv agonistas de canabinàide de benzimidazol que transportam um grupo heterocÍclico substituÍdo
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US7750007B2 (en) * 2006-11-06 2010-07-06 Supergen, Inc. Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008144305A1 (en) * 2007-05-18 2008-11-27 Janssen Pharmaceutica N.V. Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators
AR071997A1 (es) * 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina

Similar Documents

Publication Publication Date Title
JP2011522827A5 (enExample)
JP2013237682A5 (enExample)
JP2010514806A5 (enExample)
JP2010514807A5 (enExample)
JP2009149648A5 (enExample)
MX2010005925A (es) Nueva forma polimorfico de rotigotina y proceso para la produccion.
JP2013525444A5 (enExample)
JP2010535785A5 (enExample)
JP2009541216A5 (enExample)
JP2013543867A5 (enExample)
JP2012508215A5 (enExample)
NZ599770A (en) New ccr2 receptor antagonists and uses thereof
WO2012009258A3 (en) Peptidomimetic galanin receptor modulators
JP2014527042A5 (enExample)
JP2015038149A5 (enExample)
JP2007145875A5 (enExample)
RU2009122242A (ru) Кристаллические формы сольватированного илапразола
JP2021501151A5 (enExample)
JP2015522037A5 (enExample)
JP2011527333A5 (enExample)
JP2016503010A5 (enExample)
JP2011527687A5 (enExample)
JP2013503134A5 (enExample)
JP2016510768A5 (enExample)
JP2015516425A5 (enExample)